Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.69 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269800 | 1.00 | SCN9A (0.69) | SCN9ACACNA1C | |
| SCHEMBL1269798 | 1.00 | SCN9A (0.69) | SCN9ACACNA1C | |
| SCHEMBL9025761 | 0.86 | SCN9A (0.68) | SCN9A | |
| SCHEMBL15414247 | 0.85 | SCN9A (0.54) | SCN9ACACNA1C | |
| SCHEMBL15414303 | 0.85 | SCN9A (0.54) | SCN9ACACNA1C | |
| SCHEMBL15414301 | 0.85 | SCN9A (0.54) | SCN9ACACNA1C | |
| SCHEMBL9025396 | 0.84 | SCN9A (0.53) | SCN9ACACNA1C | |
| SCHEMBL12900170 | 0.82 | SCN9A (1.00) | SCN9ACACNA1C | |
| SCHEMBL29481025 | 0.81 | PYGL (0.50) | SCN9ACACNA1C | |
| SCHEMBL9023683 | 0.80 | ACE (0.52) | SCN9ACACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181946-A1 | Benzaepinones as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181946-A1 | Benzaepinones as Sodium Channel Blockers | TRPV1, TRPA1, KCNN1 | SCN9A 160/4885CACNA1C 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.